Johnson & Johnson Trading Volume Drops 25% Despite Stock Price Gains and CAR T Therapy Breakthrough

On June 25, 2025, Johnson & Johnson (JNJ) experienced a trading volume of $1.089 billion, marking a 24.99% decrease from the previous day. The stock price of JNJ rose by 0.06%, marking the third consecutive day of gains, with a cumulative increase of 1.66% over the past three days.

Johnson & Johnson's CAR T therapy has shown promising results in treating relapsed or refractory large B-cell lymphoma (LBCL). On June 13, the company announced that patients in this category demonstrated strong response rates to its dual-targeting CAR T therapy, achieving an 80% complete response rate in early lymphoma studies. This breakthrough underscores the potential of Johnson & Johnson's innovative treatments in addressing challenging medical conditions.

In a separate development, Johnson & Johnson has completed its acquisition of Intra-Cellular Therapies, which will now operate as a business unit within the company. This strategic move is expected to enhance Johnson & Johnson's capabilities in developing and delivering advanced therapeutic solutions.